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SINTESIS, PENCIRIAN DAN PENILAIAN SECARA IN VITRO BAGI 
POLIMER DISULFIDA BERANGKAI-SILANG SEBAGAI 
PENGANGKUTAN BERPOTENSI UNTUK SISTEM PENYAMPAIAN UBAT 
KHAS KEPADA KOLON 
 
ABSTRAK 
 
Sistem penyampaian drug ke kolon adalah sangat berguna untuk menyampaikan drug 
untuk rawatan penyakit kolon setempat seperti penyakit keradangan usus, ulser 
kolitis dan penyakit Crohn.  Polimer disulfida berangkai-silang telah mendapat 
perhatian kerana keupayaannya untuk bertindak sebagai polimer sensitif redoks dan  
ikatan disulfida hanya akan dilekangkan oleh persekitaran yang mempunyai potensi 
redoks yang rendah di dalam kolon.   Kebelakangan ini, polimer rantai bercabang 
disulfida telah menerima perhatian yang lebih disebabkan oleh hakikat bahawa 
polimer ini  kurang terdedah untuk degradasi dalam keadaan pH rendah di perut 
berbanding dengan polimer rantai linear disulfida. Oleh itu, tujuan kajian ini ialah 
untuk mensintesiskan monomer trithiol berasaskan asid trikarbalilik untuk 
pempolimeran ke polimer rantai bercabang disulfida.  Polimer sintetik telah dicirikan, 
dikaji secara kimia dan dinilai dengan menggunakan kajian disintegrasi secara in 
vitro.  Monomer ini telah disintesiskan melalui tindak balas gandingan amida antara 
asid trikarbalilik  dan (trifenilmetil) thioetilamina dengan menggunakan dua langkah 
sintesis.  Monomer tersebut dinyahlindungkan  dengan menggunakan asid 
trifluoroasetik dan trietilsilana untuk mendedahkan atom sulfur dalam persediaan 
untuk pempolimeran selanjutnya.    Serbuk pepejal putih diperolehi dengan hasil 
xxi 
 
lebih kurang 20-25%.  Keputusan spektroskopi dan analisis unsur CHNS 
mengesahkan monomer yang dikehendaki.  FT-IR menunjukkan kehadiran puncak 
amida dan disokong oleh analisis jisim menggunakan LC-MS.  Pempolimeran secara 
pengoksidaan N,N',N''-tris(2-sulfaniletil)propana-1,2,3-trikarboksamida (monomer 
trithiol) dan 2,2'- (etilenadioksi)dietanathiol (monomer dithiol) dengan pelbagai 
nisbah molar menghasilkan enam (6) polimer yang berbeza, dinamakan, P10, P11, 
P12, P15, P21 dan P51.  Spektroskopi Raman menunjukkan kemunculan ikatan 
disulfida.  Kajian reduksi kimia menunjukkan bahawa semua polimer disulfida telah 
diturunkan dengan lengkapnya selepas 1 jam dengan kepekatan thiol yang berbeza.  
Dalam keadaan simulasi gastrik dan usus kecil, semua polimer menunjukkan 
kepekatan thiol yang rendah jika dibandingkan dengan kepekatan thiol yang dikesan 
dalam keadaan simulasi kolon dengan kehadiran Bacteroides fragilis.  Keputusan ini 
membuktikan bahawa semua polimer disulfida dapat bertahan dalam persekitaran 
gastrik dan usus kecil yang kasar dan degradasi hanya akan berlaku dengan 
kehadiran bakteria anaerobik di kolon.  Degradasi didapati lebih ketara dalam 
polimer P15 menunjukkan kepekatan thiol yang tertinggi, iaitu 57 x 10
-6
 mol L
-1
 
berbanding  polimer yang lain.  Keputusan ini memberi persetujuan umum bahawa 
biodegradabiliti bergantung pada kebolehkembangan polimer-polimer ini dalam 
keadaan akues. Penyelidikan ini telah mengidentifikasikan polimer berangkai silang 
disulfida yang mungkin mempunyai potensi untuk sasaran ke kolon.  Walau 
bagaimanapun, kajian selanjutnya  diperlukan bagi mencapai kestabilan dan 
penggunaannya sebagai polimer dalam bentuk dosaj farmaseutikal.  
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SYNTHESIS, CHARACTERISATION AND IN VITRO EVALUATION OF 
DISULPHIDE CROSS-LINKED POLYMERS AS POTENTIAL CARRIERS 
FOR COLON SPECIFIC DRUG DELIVERY SYSTEM 
 
ABSTRACT 
 
Colon drug delivery system is very useful to deliver drugs for treatment of localised 
colonic diseases such as inflammatory bowel disease, ulcerative colitis and Crohn’s 
disease.  Disulphide cross-linked polymer has received much attention because of its 
ability to act as a redox sensitive polymer and will only be cleaved by the low redox 
potential environment in the colon.  Recently, branch-chained disulphide polymers 
had received more attention due to the fact that it is less susceptible for degradation 
in low pH condition of the stomach compared to linear-chained disulphide polymers.  
Therefore, the aim of this work is to synthesise tricarballylic acid based trithiol 
monomer for polymerisation into branch-chained disulphide polymers.  The 
synthesised polymers were characterised, studied chemically and evaluated using in 
vitro disintegration studies.  The monomer was synthesised by amide coupling 
reaction between tricarballylic acid and (triphenylmethyl) thioethylamine by using 
two synthetic steps.  The monomer was deprotected using trifluoroacetic acid and 
triethylsilane to expose the sulphur atoms in preparation for further polymerisation.  
White powdery solid was obtained with yield around 20-25%.  Spectroscopic and 
CHNS elemental analysis results complemented with the desired monomer.  FT-IR 
showed the presence of amide peaks and supported by the mass analysis using LC-
MS.  The oxidative polymerisation of N,N',N''-tris(2-sulfanylethyl)propane-1,2,3-
tricarboxamide (trithiol monomer) and 2,2’-(ethylenedioxy)diethanethiol (dithiol 
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monomer) of various molar ratios resulted   six (6) different polymers, namely, P10, 
P11, P12, P15, P21 and P51.  Raman spectroscopy demonstrated the emergence of 
disulphide bond.  Chemical reduction studies showed that all the disulphide polymers 
were completely reduced after 1 hour of reduction with different thiol concentrations.     
In simulated gastric and intestinal condition, all the polymers showed low thiol 
concentrations when compared to the detected thiol concentrations in simulated 
colon condition with the presence of Bacteroides fragilis.  The results proved that all 
the disulphide polymers were able to withstand the harsh environment of the gastric 
and intestinal condition and degradation will only occur in the colon condition with 
the presence of anaerobic colonic bacteria.  Disintegration was found to be more 
pronounced in polymer P15 as the highest thiol concentration of 57 x 10
-6
 mol L
-1
 
among all the other polymers.  This result correlated the general consensus that 
biodegradability relies on the swelling ability of polymers in an aqueous environment.  
This work has successfully identified a disulphide cross-linked polymer, which might 
be potential for colon specific targeting.  However, further study on these polymers is 
required to establish the stability and use of the polymer within a pharmaceutical 
dosage form. 
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CHAPTER ONE 
INTRODUCTION 
 
1.1 Background 
To date, oral drug delivery is the most preferred, common, convenience and widely 
accepted route among many other routes of drug administration (Rubinstein, 1995; 
Laura et al., 2011).  Upper gastrointestinal (GI) tract appeared to be the major region 
for dissolution and absorption of orally administered drug.  However, this approach 
is not suitable for drugs to be absorbed in lower GI tract or advanced biotechnology 
products such as peptides and proteins, whereby undesirable side effects and 
treatment failure will occur.  Therefore, studies had been done in developing specific 
drug targeting especially to lower GI tract.  Colon specific drug delivery had 
received much interest with much work already been carried out in this area of drug 
delivery (Yan et al., 2010; Kenawy et al., 2011; Ursekar et al., 2012; Lim et al., 
2013).  The role of colon specific drug delivery is not only limited for localised 
treatment but also crucial for systematic treatment (Tozer et al., 1995).  Although 
colon specific drug delivery can also be achieved via rectal route but this route 
appeared to be less readily accepted and less appealing to patients.  Moreover, study 
showed that it is difficult to deliver drug to the proximal colon via the rectal route 
(Ritschel, 1991). 
 
Colon specific drug delivery is particularly important in localised treatment of colon 
diseases such as inflammatory bowel disease (IBD), ulcerative colitis, Crohn’s 
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disease and colorectal cancer (Gupta et al., 2001; Rubinstein, 2005; Yan et al., 2010).  
The nature of colon which is less hostile has a near neutral pH and lower activity of 
peptidase enzyme favours the systemic absorption of protein and peptide drugs 
(Maroni et al., 2012). 
 
1.2 Anatomy of the colon 
The GI digestive tract is a system of organs in human which responsible in taking 
food, digesting it to extract energy and nutrients and eliminating waste.  The normal 
human adult male GI tract consists of the upper and lower GI tracts and is 
approximately 6.5 meters long (Anthea et al., 1993). 
 
The colon, or large intestine, is located at the distal end of the GI tract (Figure 1.1).  
It is a muscular tube with a length of approximately 1.5 m long, has an average 
diameter of approximately 6.5 cm, with a diameter that varies from 2 cm in the 
sigmoid colon to 9 cm in the caecal region, running from the ileocaecal valve to the 
anus (Cummings and MacFarlane, 1991).  The human colon is composed of the 
caecum, ascending segment, transverse segment, descending segment and sigmoid 
region.  Colon plays an important role in extracting water and salt from solid wastes 
before they are eliminated from the body, storing waste, absorbing some vitamins 
and providing a site for flora-aided fermentation.  Unlike the small intestine, the 
colon does not play a major role in absorption of foods and nutrients.  Colon does not 
have villi although it does demonstrate crescentric folds, which increase the internal 
surface area of the colon to approximately of 1300 cm
2
 (Cummings and MacFarlane, 
1991).  Guinea pigs and rodents models were commonly used in the study of colonic 
 3 
 
drug delivery (Friend, 1991).  However, there are differences between the animal 
models with normal human.  The guinea pig has a very large caecum whereas 
humans have a poorly defined caecal region continuous with the colon (Friend, 1991).  
The transit time was found to be shorter in guinea pigs and slightly longer in rats if 
compared to humans (Pettersson et al., 1976).  The mucosa of the colon is lined 
almost entirely by goblet mucus secreting cells, whereby the large amount of 
bicarbonate ions from the mucus maintains the basic pH of the colonic region 
(Binder and Sandle, 1994). 
 
 
Figure 1.1 : Structure of the colon (large intestine) (after Wikipedia, 2014). 
 4 
 
1.3 Microflora of the gastrointestinal tract 
The upper GI tract is sparsely populated with micro-organisms.  The acidic 
environment of the stomach exhibits a strong bactericidal activity, whereby the 
microbial concentration is usually less than 10
3
 cfu/ml (Ilett et al., 1990).  Acid-
tolerant micro-organisms such as gram-positive aerobic streptococci and lactobacilli 
are the main inhabitants in the stomach (Hao and Lee, 2004).  The upper two-thirds 
of the small intestine which includes duodenum and jejunum contain similar bacterial 
concentration to the stomach, between 10
3
 to 10
4
 cfu/ml.  However, gram-negative 
bacteria begin to outnumber gram-positive bacteria in the distal ileum. The reduction 
in acidity and lower redox potentials play a major role in maintaining a more diverse 
microflora and higher bacteria population (Tannock, 1983).   
 
Colon is the primary site of microbial colonisation in human body.  The colon 
contains a very large quantity of bacteria from various species.  The bacterial 
concentration in the colon is around 10
11
 to 10
12
 cfu/ml and approximately one third 
of the fecal dry weight consists of bacteria (Simon and Gorbach, 1984).  The increase 
in bacterial concentration in this region is due to a near neutral pH caused by 
neutralisation of the bowel contents by intestinal juice and lower motility rate of the 
colon.  However, 99.9 % of colonic microflora is obligate anaerobes (Hao and Lee, 
2004).  There are over 400 different bacterial species found in the colonic region.  
The predominant species isolated include Bacteroides, Eubacterium, Bifidobacterium 
(Hill and Drasar, 1975).  Anaerobic gram-positive Cocci, Enterococci, Clostridia and 
other species of Enterobacteriaceae, Coliforms, Staphylococci, Lactobacillus, 
Spirochetes, Pseudomonas, Proteus, Clostridium, Actinomyces, Borrelia, 
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Fusobacterium and Diphtheroides species are also found.  However, Bacteroides 
species account for nearly 32 % of all bacterial flora isolated from the GI tract 
(Finegold et al., 1977).  The comparison of microbial concentration in different 
regions of GI tract is shown in Figure 1.2. 
 
 
Figure 1.2 : Concentration of microflora in different regions of gastrointestinal tract 
(taken with modification from Basit, 2005). 
 
Certain diseases or antibiotic treatment will influence the microbial flora in the gut 
(Friend and Tozer, 1992).  The nature of certain disease, where reduction of gastric 
acid secretion occurred, will lead to increase in bacterial growth in the stomach 
(Rowland, 1988).  The speed of peristalsis movement decreases from the jejunum to 
upper ileum and the distal ileum.  As it is approaching the ileo-caecal valve, 
peristalsis slows down to an almost stagnant state and this has been the major factor 
which cause the drastic rise in the bacterial population in this area.  The bacteria 
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populations found in this area are mainly Bacteroides, Enterobacteria and 
Bifidobacteria.  Huge changes of some organisms in the region within the gut can 
occur when antibiotic treatments are introduced where it has bactericidal effect and 
suppresses the bacterial growth (Goldin and Grobach, 1977). 
 
Colon is well known for its reductive environment, where the redox potential 
becomes more negative from the small intestine to the large bowel.  The redox 
potential of proximal small bowel is -67 ± 90 mV, -196 ± 97 mV in the distal small 
bowel and -415 ± 72 mV in the colon (Stirrup et al., 1990).  The presence of the 
bacterial microflora causes the changes in the redox potential along the GI tract.  Due 
to its low redox potential, the colonic region is very active in reductive and 
degradative reactions (Rowland, 1986).   
 
Bacterial microflora in the GI tract produce a wide range of reductive and hydrolytic 
enzymes which include β-glucoronidase, β-galactosidase, β-xylosidase, azoreductase, 
nitroreductase, urea hyroxlase and α-arabinosidase (Kinget et al., 1998).  The ability 
of colonic anaerobic bacteria to produce appropriate digestive enzyme in order to 
digest the constantly changing carbohydrates complex was exploited for the 
development of enzyme-sensitive prodrugs to achieve colonic drug targeting (Sinha 
and Kumria, 2001a; Sinha and Kumria, 2001b).   
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1.4 Colon-specific drug targeting 
The concept of delivering drug to the desired site is not new.  All drugs exert their 
beneficial effects along with undesirable side effects to varying degrees of severity.  
Therefore, site-specific drug delivery is important by enhancing the beneficial effects 
and limiting the side effects.  The formulated dosage form for colon-specific drug 
delivery must pass through the upper GI tract intact before delivering the drug to the 
colonic region.   
 
Physiological factors in the upper GI tract such as extreme acidity in stomach, 
degradative enzyme activities and presence of bile salts will destroy the drug 
molecules that are intended to colon, especially peptides and proteins.  This will 
result in poor bioavailability of drugs and treatment outcome.  Due to the barriers of 
the upper GI tract, colon has been focused as the targeting site for orally 
administered drug.  Numerous investigations have shown that some anti-
inflammatory (Wilson and Washington, 1989) and antidiabetic (Gleiter et al., 1985) 
drugs are better absorbed from the colon rather than the upper GI tract.   
 
The colon is found to have prolonged residence time for the colonic contents (Coupe 
et al., 1991).  The average transit time through the colon is 22-36 hours and it is 
much higher if compared to the transit time in the stomach (0.5-3 hours) and the 
small intestine (1-6 hours) (Coupe et al., 1991).  On top of that, colonic transit time 
has been shown to be independent of size and density of the dosage form (Parker et 
al., 1988).  The ideal property for a colon-specific drug delivery system is to spend 
as little time as possible in the upper GI tract (Friend, 1991).  Therefore, the 
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prolonged colonic transit time provides a longer time interval for drug absorption in 
the colonic region.  This will compensate the smaller surface area for absorption in 
the colon compared to the small intestine.  
 
1.5 Strategies for targeting drugs to the colon 
The main responsibility of a colonic drug delivery system is to utilise the special 
characterisitics of the colon in order to achieve localised drug release.  The main 
concept of orally administered colon-specific drug delivery is where the dosage form 
must be able to withstand the harsh environment of the stomach and small intestine 
but to achieve drug release in the colon.  The major characteristics of the GI tract 
include pH, transit time, enzymes, bacteria and pressure (Basit, 2005; Bhalerao and 
Patel, 2012) were taken into considerations in order to develop a good formulation 
for colonic drug delivery.  These strategies are currently being studied and will be 
further discussed below. 
 
1.5.1 pH responsive delivery 
pH in human GI tract changes when it shifts from one region to another.  The 
environment of the stomach is acidic (pH 1-2) and the pH increases in the small 
intestine region (pH 6.5-7).  The pH in the terminal ileum and colon (pH 7-8) is the 
highest in the human GI tract.  The concept of pH responsive delivery was designed 
by using materials that are insoluble in acidic pH but dissolve in neutral to slightly 
basic pH (Ibekwe et al., 2006).  However, pH in the terminal ileum region is higher 
than in the caecum.  Thus, the dosage forms are often delayed at the ileocecal 
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junction.  In short, the concept of using polymers that are sensitive to higher pH was 
employed and adapted for colonic drug delivery instead of conventional enteric 
coating (Edsbacker and Anderson, 2004). 
 
Acrylic polymers from the Eudragit® range are commonly used for this purpose 
because of its solubility when expose to pH above 6 (Basit, 2005).  Eudragit-based 
polymers can be made to dissolve at various basic pH by modifying the methylester 
content (Peeters and Kinget, 1993).  Eudragit® S and Eudragit® L were designed to 
be specifically dissolved in pH 7 and pH 6 respectively.  Dew et al. (1982) were the 
first to employ Eudragit® S as a capsule coating by utilising gastrointestinal pH as a 
trigger for drug release in the distal gut.  The results were positive in most patients as 
the capsule disintegrated in the distal gut.  However, Ashford et al. (1993a, 1993b) 
found that the drug release of Eudragit® S-coated tablets in the colon of healthy 
volunteers was not adequately reproducible.  The reason behind was due to the 
decrease in pH after passage through the ileocaecal valve.  Therefore, Eudragit® S 
coating dissolves and releases its drug content in the ileum rather than colon.   
 
Despite such evidence of premature release of drug contents in the ileum, 
preparations include Asacol
®
 (Eudragit® S) and Claveral
®
 (Eudragit® L) have been 
formulated using which have approval for human use.  The preparations were found 
to be successful in treatment of IBD (Hardy et al., 1987).  In order to compensate the 
low release pH of Eudragit® L, a thicker layer was formulated.  The release of drug 
contents (5-aminosalycilic acid) from both preparations is reported to take place at 
the distal ileum and right colon. 
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1.5.2 Time responsive delivery 
The size, shape and density of the dosage form and the feed status of the individual 
are the major factors which will affect the GI transit time (Davis et al., 1984; 
Devereux et al., 1990).  Residence time in the stomach varies from a few seconds to 
few hours.  However, small intestine transit time was found to be more consistent at 
3-4 hours, without being affected by feed status of the individual (Davis et al., 1986).  
The consistent transit time of small intestine has been exploited in developing colon 
drug delivery system.  Time responsive delivery is formulated to release their drug 
contents after a predetermined lag time.  Assumption was made by researchers, 
whereby 5-6 hours are needed for the ingested dosage form to reach the colonic 
region.  Therefore, a nominal lag time of 5 hours is usually considered sufficient 
(Davis et al., 1986).  
 
The pioneer time responsive delivery system was developed by Wilding et al. (1992), 
namely, Pulsincap
TM 
device.  The device consists of an impermeable hard gelatin 
capsule sealed at one end with hydrogel plug.  Upon contact with gastrointestinal 
fluid, the plug hydrates and begins to swell and after a pre-set lag time, ejects from 
the capsule body, enabling drug release to occur.  The size and composition of the 
plug are crucial in controlling the lag time of the entire device.  Two different 
Pulsincap
TM
 devices with different pre-set lag time of 5 and 6 hours respectively 
were studied in fasted human subjects using gamma scintigraphy (Hebden et al., 
1999).  The authors found that the location of the device varied in human body at the 
time of release.  Further study reported that the device exhibits poor emptying feature 
 11 
 
especially in distal bowel.  Lack of fluid in the distal bowel appeared to be the major 
factor which caused the drawback (Wilding, 2000).     
 
Newer colon drug delivery system was described by merging of both pH and time 
responsive mechanisms in order to increase the effectiveness (Ishibashi et al., 1998).  
The system comprises of a conventional hard gelatin capsule which contains mixture 
of drug content and organic acid.  The outer surface of the capsule is coated with 
three layers, including outer enteric layer, hydrophilic layer and acid-soluble layer.  
The entire system was designed to survive in the harsh condition of the stomach.  
Subsequently, the capsule will reach a higher pH condition in the small intestine, 
whereby the outer enteric layer will dissolve followed by the intermediate 
hydrophilic layer.  The inner acid-soluble layer which dissolves at pH below 5 will 
survive the condition of the intestine.  However, fluid will enter the capsule and lead 
to the dissolution of the organic acid.  pH reduction occurs followed by the 
dissolution of the acid-soluble layer, leading to drug release from the entire system.  
Study was done on fasted and fed volunteers but the results showed variability for 
the site of disintegration (Ishibashi et al., 1998).   
 
From the report of several studies, individual variability is a major influence towards 
the gastrointestinal transit time (Coupe et al., 1991).  Moreover, transit was found to 
be faster in the morning if compared to the evening (Hebden et al., 1999).  Time 
responsive delivery system was unable to detect individual’s gastrointestinal transit, 
which limits the practicality of the formulation. 
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1.5.3 Pressure responsive delivery 
Higher pressures are encountered in the colon as a result of peristalsis movement.  
The grinding, propulsion and motility of the luminal contents were found to be 
generating pressure due to the muscle contraction of the intestinal wall.  However, 
the intensity and duration of the generated pressure varies throughout the GI tract 
(Takaya et al., 1995).  The colon is believed to exert a higher effective luminal 
pressure in a viscous environment.  A capsule utilising pressure responsive system 
was developed by Takaya et al. (1995), using a hydrophobic polymer ethycellulose.  
Drug release can be achieved after the successful disintegration of the capsule due to 
the luminal pressure of the colon.  The thickness of the ethylcellulose layer plays a 
crucial role for the disintegration of the dosage form. 
 
Several works had been done on methods of manufacturing pressure responsive 
delivery system.  Takaya et al. (1995) had successfully coated the inner surface of 
the gelatin capsule with hydrophobic ethylcellulose, Hu et al. (2000) reported a low 
temperature coating of the capsule-shaped pieces of suppository base.  The dipping 
method into both ethanolic ethylcellulose and alkalised enteric polymer solution was 
conducted by Jeong et al. (2001).  Investigations were made for these formulations 
which involved pharmacokinetic evaluation.  Correlation between times for 
appearance of drug in plasma with literature values for colon arrival times had been 
done.  However, the results did not conclusively show successful disintegration in 
the colon due to gastric and intestine transit times are known to be variable. 
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1.5.4 Bacteria responsive delivery 
Majority of the bacteria in the human colon are anaerobic in nature.  These anaerobic 
bacteria are responsible in producing various types of enzyme to metabolise 
substrates, such as proteins and carbohydrates, which escape from the upper GI tract 
(Cummings et al., 1989).  Materials which are susceptible to the enzymatic 
degradation in the colon but able to survive the condition of gastric and small 
intestine, could be designed as carriers for colonic drug targeting.  These enzyme 
sensitive materials depend heavily on the enzyme-generating microflora in the colon.  
The enzymes generated include azoreductase, peptidase, esterase and glycosidase.  
To date, bacteria responsive colon drug delivery has received much attention 
(Vandamme et al., 2002; Sinha and Kumria, 2003; Chourasia and Jain, 2004; Ibekwe 
et al., 2008).  
 
1.5.4.1Azo-containing prodrugs 
Sulphasalazine appeared to be the first bacteria responsive colon drug delivery 
system being invented.  It is a prodrug consisting of the active drug content 
(mesalazine) linked by an azo bond to a carrier molecule (sulphapyridine) 
(Peppercorn and Goldman, 1972; Svartz, 1988).  From the study done by Myers et al. 
(1987), mesalazine was found to be rapidly absorbed from the small intestine.  
However, absorption is inhibited in the gastric and small intestine until it reaches 
colon when the prodrug is ingested.  Bacteria in the colon will release enzyme such 
as azo-reductase to cleave the azo bond of the prodrug, leading to release of the 
active drug content of 5-aminosalicylic acid (5-ASA) at the inflammation region.  
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Klotz (1985) reported that approximately 85% of an orally administered 
sulphasalazine survived unabsorbed into the colonic region. 
 
Enzymatic reduction will break down sulphasalazine into 5-aminosalicylic acid (5-
ASA) and sulphapyridine as shown in Figure 1.3.  5-ASA is generally unabsorbed in 
the colon where it is responsible in providing topical anti-inflammatory activity 
(Peppercon, 1984).  However, sulphapyridine is well absorbed in the colon (Klotz, 
1985) and causes undesirable side effects such as allergic reactions, which occurs in 
up to 50% of recipients. 
 
 
 
Figure 1.3 : Mechanism of enzymatic reduction of sulphasalazine in the colon. 
 
Sulphasalazine 
Enzymatic reduction 
5-aminosalicylic acid Sulphapyridine 
 15 
 
In order to solve the toxicity issue of sulphapyridine, mesalazine has been azo 
bonded to another mesalazine molecule, namely olsalazine (Campbell and Berlingdh, 
1998) or inert carrier, namely balsalazide and ipsalazide (Chan et al., 1983).  
Molecular structures of olsalazine, balsalazide and ipsalazide are shown in Figure 1.4.  
These methods provide alternative prodrugs for use in IBD which can prevent the 
toxicity problem of sulphapyridine. 
 
 
 
Figure 1.4 : Molecular structure of new-generation prodrugs of 5-ASA. 
Olsalazine 
Balsalazide 
Ipsalazide 
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1.5.4.2 Azo-polymers 
Azo-reductase is a type of enzyme which is commonly found in human colon.  The 
use of bacterial azo-reductase to split prodrug sulphasalazine into sulphapyridine and 
5-ASA was the first colon specific targeting system.  Subsequently, several studies 
were carried out by exploiting the azo-reductase enzyme as a release mechanism for 
drugs within the colonic region.  Coating of peptide insulin with polymers cross-
linked with azoaromatic group has been discovered to protect insulin from the harsh 
environment of stomach and small intestine.  Thereafter, azo bonds were reduced in 
the colon, leading to the release of insulin (Saffran et al., 1986).  Further study was 
conducted to deliver similarly coated insulin dosage forms to the colon of diabetic 
dogs (Saffran et al., 1990) and the release mechanism was concluded to be caused by 
the enzymatic degradation of the azo-polymer coatings in the colon.  The increase in 
insulin level and reduction in glucose production and glucose level were found to be 
statistically significant.   
 
Copolymers were employed for potential colon drug targeting by Van den Mooter et 
al. (1992, 1993 and 1995).  Copolymers composing of 2-hydroxyethyl methacrylate 
(HEMA) and methylmethacrylate (MMA) were prepared in the presence of a 
bifunctional azo compound, which is bis(methacryloylamino)azobenzene (BMAAB).  
Different molar ratios of HEMA and MMA were used in order to obtain different 
copolymers.  Copolymer comprised of 1:6 molar ratio of MMA/HEMA and polymer 
without the addition of MMA showed significant bacterial reduction both in vitro 
and in vivo.  Both of the polymers demonstrated good resistant in simulated gastric 
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acid and intestinal fluid.  Conclusions were made that the monomer composition has 
a greater influence than the structure of the cross-linking agent.   
 
Hydrophilic azo-polyamides were studied as a potential colonic drug targeting by 
Schact et al. (1991).  The films were found to be completely dissolved under 
reductive medium (-430 mV) and simulated human intestinal microbial ecosystem 
(SHIME).  The degradation was detected by observing the colour changes from pink-
orange to white/colourless.  Lloyd et al. (1994) suggested that complete reduction of 
azo bonds to amine would be favorable for effective drug release.  Hydrophilic 
polymers appeared to meet the requirement because of reduction of such polymers 
are reported to go toward amine formation.  Meanwhile, hydrophobic polymers 
reduction stops at the hydrazo stage which appeared to be undesirable (Schact et al., 
1996).  Recent studies showed similar results in degradation of azo dyes by bacteria 
(Pandey et al., 2007; Hong et al., 2008). 
 
1.5.4.3 Glycosidic prodrugs 
Colonic bacteria provide glycosidase activity by generating glycosidase enzyme 
which forms the fundamental of a colon specific drug delivery system.  Friend and 
Chang (1984 and 1985) utilised corticosteroid prodrugs as glycosidic carrier by the 
attachment of the active agent.  Drug glycosides are poorly absorbed from small 
intestine due to its hydrophilic nature.  The drug glycosides can be cleaved by 
glycosidase enzyme upon reaching colonic region, releasing the active drug contents 
which will be absorb by the colonic mucosa.  Several studies have reported that 
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absorption occur for corticosteroids obtained from hydrolysis of glycosidic prodrug 
in the colonic region.   
 
Strategy of glycosidic prodrug was evaluated in rats with two steroid prodrugs, 
prednisolone 21-β-D-glucoside and dexamethasone 21-β-D-glucoside (Tozer et al., 
1991).   The potential of glycosidic prodrug is assessed by determining the rates of 
its hydrolysis down the alimentary canal of the guinea pig.  It was found that the 
caecum and colon contents showed greater hydrolytic activity than the stomach and 
small intestine contents.  On top of that, the movement and hydrolysis of the prodrug 
down the GI tract of the guinea pig were also examined.  The authors reported 
approximately 20 to 30 % of an oral dose appeared to reach the caecum, whereby the 
prodrug was rapidly hydrolysed to the active form.  Greater site-specific delivery is 
expected for human due to less glucosidase activity in the small intestine. 
 
1.5.4.4 Polysaccharides 
Natural or synthetic polysaccharides have received much attention for colon specific 
drug delivery.  The feature of natural polysaccharides which can be degraded by the 
local bacterial enzyme upon entering colonic region was exploited for colon drug 
delivery (MacFarlane and Cummings, 1991).  These natural polysaccharides are 
present in normal dietary food and usually are resistant to digestive enzyme in the 
upper GI tract.  Many of these polymers are already used as pharmaceutical 
excipients in formulations.  Therefore, problems associated with toxicity and 
biocompatibility are much simplified.  However, the hydrophilic nature of the 
polysaccharides would cause swelling in the upper GI tract and eventually lead to 
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premature drug release.  Thus, methods were developed to prevent premature drug 
release by either chemically modified the polymers and mixed with hydrophobic 
polymers.  This will prevent the swelling in the upper GI tract, but still retaining the 
solubilisation feature of the coating in the colon due to bacterial degradation.   
 
Several studies have been done on the use of dextrans in colonic drug delivery 
(Harboe et al., 1988; McLeod et al., 1993).  Dextran has potential to act as a carrier 
for drugs such as naproxen and dexamethasone.  The authors reported that 
degradation of dextran was significantly higher in colon if compared to upper GI 
tract.  Modification has been made for dextran by esterification with fatty acids in 
order to reduce its solubility (Hirsch et al., 1995).  In vitro degradation studies 
showed that the modified dextran resisted the harsh condition of the upper GI tract, 
but sensitive to degradation by colonic microflora.  However, increment in degree of 
crosslinking will render the reduction of colonic degradability of the polymer. 
 
Pectinolytic enzymes found in the colonic region are responsible in the degradation 
of pectin (Rubinstein and Sintov, 1992).  This unique feature was exploited by the 
researchers which pectin was used as a carrier for colonic drug delivery (Ashford et 
al., 1994).  Pectin Type 170 (30-40 % methoxylated) and Pectin USP (70 % 
methoxlated) were used as a compression coating.  A minimum thickness of 0.9 mm 
(700 mg) of Pectin USP coat was found to be viable in resisting the intestinal 
condition.  However, a thicker coat of 1000 mg showed poor degradation in 
pectinolytic enzyme medium due to poor penetration of fluid to hydrate the coating 
for enzyme entry.  From the scintigraphic result, pectin coating is able to protect the 
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drug until colonic region and majority of the release occurred in caecum and 
ascending colonic region.  Modification was made by cross-linking calcium with 
pectin, yielding calcium pectinate (Adkin et al., 1997).  The authors reported that 
calcium pectinate tablets were degraded in rat caecum, whereby such modification 
has potential for colonic drug delivery. 
 
Guar gum is a galactomannan which has high viscosity.  This polysaccharide has 
potential to be used as a carrier, delivering drugs to the colon without undesirable 
release in the upper GI tract.  The potential of guar gum has been studied in the form 
of a matrix and compression coat (Rubinstein and Gliko-Kabir, 1997; Krishnaiah et 
al., 1998a and 1998b; Tugcu-Demiroz et al., 2004).  A study utilising guar gum 
compression coat of 400 mg that applied to tablet cores of 300 mg, containing 250 
mg of ornidazole was found to be significantly delay the onset of drug release and 
absorption (Krishnaiah et al., 2003).  However, the drug from the coated formulation 
was found to be absorbed in a slower rate from the colon.   
 
Amylose is one of the major components of starch, apart from amylopectin 
(Biliaderis, 1991).  Amylose is susceptible to fermentation by a broad range of 
colonic bacteria (Salyers et al., 1977), where more than half of the bacterial 
population is able to digest amylose (MacFarlane and Englyst, 1986).  The 
polysaccharide amylose has been exploited as a carrier for colonic drug delivery in 
the form of film coating (Siew et al., 2000; Leong et al., 2002).  Addition of 
hydrophobic ethylcellulose as a structuring agent is essential due to the fact that 
amylose films tend to swell in aqueous media.  Various ratios of amylose with 
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ethylcellulose were employed to investigate the applicability in colonic drug delivery.  
Drug release from the coated formulations was reported in fermentation environment 
of the colon.  Therefore, amylose coated formulations have potential to become a 
carrier for drug delivery to the colon. 
 
1.5.4.5 Disulphide polymers 
To date, disulphide polymers have received much interest due to its potential as 
carrier for colonic drug delivery.  Disulphide polymer was found to be resistant in the 
upper GI tract but susceptible to degradation in the colonic region.  Low redox 
potential environment of the human colon is the key feature for the entire mechanism, 
where disulphide bond will be reduced.  It has been proposed that linear polymers 
containing disulphide backbones could be degraded in the low redox potential 
environment of the human colon (Schact and Wilding, 1991).  Watts and Illum (1997) 
reported that the tablets coated with polymer rapidly disintegrated, achieving 
complete dissolution in the testing medium. 
 
Recently, studies were focused on employing branch-chained disulphide polymers 
instead of linear-chained.  The major reason was due to the insolubility features of 
the branch-chained polymers.   Linear-chained polymers are easily degraded in low 
pH condition and more soluble if compared to branch-chained polymers (Sahudin, 
2001; Lim et al., 2013).  The ability of disulphide polymers to degrade in low redox 
potential of the colonic environment while sustaining the harsh environment of the 
upper GI tract, have been exploited as a redox-sensitive polymers in colon-specific 
drug delivery.   
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1.6 Literature review 
Protection of the thiol group is crucial in many areas of organic research especially in 
peptide synthesis. The thiol groups were found to be very reactive and therefore the 
protection is necessary for the sulphur atom.  A free thiol group can be protected as a 
thioether or thioester. The protecting group can be easily cleaved via acidic 
hydrolysis or by using sodium/ammonia (Wuts and Greene, 2006).  Triphenylmethyl 
thioether protecting group which is used in this synthesis can be remove by using 
iodine, thallium trifluoroacetate and trifluoroacetic acid (TFA).  Iodine and thallium 
are not favorable as a deprotection agent because they will effect simultaneous 
disulphide bond formation (Fields and Noble, 1990).  Relatively, TFA is a more 
favorable agent because it generates free thiol groups without forming disulphide 
bond (Atherton and Sheppard, 1987).  However, the using of TFA alone for the 
deprotection procedure is not sufficient.  The cleavage reaction is reversible due to 
the high stability of the trityl cation and strong nucleophilic nature of the thiol group.  
Hence, the use of triethylsilane (TES) scavengers appeared to be crucial in the 
deprotection process.  TES will quench the trityl carbocation to form 
triphenylmethane and make the entire process irreversible (Figure 1.5) (Pearson et.al. 
1989). 
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b) 
 
 
 
Figure 1.5 : TFA deprotection of triphenylmethyl (a) and TFA/TES scavenger 
deprotection of triphenylmethyl (b). 
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Linear disulphide polymers have been studied shown to be biodegradable in colonic 
bacterial culture (Le, 1998).  Such polymers have been suggested as the coating 
materials for colon drug delivery system (Schacht and Wilding, 1991).  However, 
linear-chained disulphide polymers were found to be easily degraded in low pH 
condition of the stomach (Sahudin, 2001).  Therefore, branch-chained disulphide 
polymers had received more attention due to less susceptible for degradation in low 
pH condition of the stomach and more insoluble compared to linear-chained 
disulphide polymers.  Nevertheless, the insolubility feature of branch-chained 
disulphide polymers would appear to be desirable in the stomach and small intestine 
if the polymerisation of the polymers can be controlled.  The important goal of the 
polymer is to maintain the dosage form in an intact state and should be readily 
degraded in low redox potential environment of the human colonic region.   
 
Oxidative polymerisation method can be used for synthesis of disulphide cross-
linked polymer where the monomer is placed in a mild basic condition, exposed to 
open air and with the presence of oxidising agent such as dimethyl sulphoxide 
(DMSO) (Tan et al. 1991).  DMSO is miscible with water at all concentrations, thus 
it helps to improve the solubility of thiol monomers in aqueous solution.  The 
reaction mechanism of oxidation by DMSO was shown in Figure 1.6. 
 
 
 
 
